Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand

Globus Medical (GMED) delivered a robust Q2 2025, with adjusted EPS of $0.86, up 14.1% year-over-year and exceeding estimates by 13.16%. Revenues climbed 18.4% to $745.3 million, also beating expectations, aided by the Nevro acquisition. Notably, gross margin expanded 792 basis points to 66.6% and adjusted operating margin surged 584 basis points to 20.5%, indicating strong operational efficiency. This solid performance, driven by momentum in the U.S. Spine business, led to a 14.4% stock increase and the reaffirmation of full-year 2025 guidance.

Analysis

Globus Medical (GMED) reported a robust second quarter for 2025, with both revenue and earnings surpassing consensus estimates. Revenue grew 18.4% year-over-year to $745.3 million, driven significantly by a $95 million contribution from the newly acquired Nevro. The core Musculoskeletal Solutions segment posted strong growth of 19.8%, while the smaller Enabling Technologies segment contracted by 4.4%. A key highlight was the substantial improvement in profitability; gross margin expanded by 792 basis points to 66.6% and the adjusted operating margin surged 584 basis points to 20.5%, indicating significant operational leverage and cost control as the cost of sales declined 4.3%. This margin expansion occurred despite a 26.8% increase in SG&A expenses. The company's U.S. business was a primary growth engine, with sales increasing 20.3%. Cash flow from operations more than doubled to $255.2 million, reinforcing the quality of the earnings beat. Despite the strong quarterly performance and a 14.4% stock price increase following the news, the company reaffirmed its full-year 2025 guidance, with consensus estimates for sales and EPS falling comfortably within the projected ranges.

Key Decisions for Investors

• Investors should view the significant gross and operating margin expansion as a key positive, validating the company's operational efficiency and the successful early-stage integration of the Nevro acquisition.
• It is critical to monitor the performance of the core Musculoskeletal Solutions segment against the 4.4% revenue decline in Enabling Technologies to ensure overall growth momentum is sustained.
• Given the stock's recent 14.4% appreciation and the company's decision to reaffirm rather than raise guidance, investors should consider if the strong quarterly performance is already reflected in the current valuation, a sentiment echoed by the neutral Zacks Rank #3 (Hold) rating.